Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CCKAR | P32238 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709900 | 0.93 | NPC1 (0.47) | NPC1LMNARAB9ASMN1; SMN2CCKAR | |
| SCHEMBL6711741 | 0.92 | HIF1A (0.47) | HIF1ANPSR1RXFP1 | |
| SCHEMBL6713465 | 0.92 | GPR35 (0.43) | HIF1ANPSR1RXFP1 | |
| SCHEMBL6707953 | 0.90 | MAP3K5 (0.45) | LMNAHIF1ANPSR1RXFP1 | |
| SCHEMBL6711906 | 0.89 | NHERF1 (0.46) | NPC1LMNARAB9ASMN1; SMN2CCKAR | |
| SCHEMBL6707650 | 0.89 | P2RX1 (0.39) | NPC1LMNARAB9AHIF1ANPSR1 | |
| SCHEMBL6708158 | 0.88 | GPR35 (0.38) | LMNAHIF1ANPSR1RXFP1 | |
| SCHEMBL6710241 | 0.88 | GPR35 (0.43) | LMNASMN1; SMN2HIF1ANPSR1RXFP1 | |
| SCHEMBL6710320 | 0.87 | PARP14 (0.39) | LMNAHIF1ANPSR1RXFP1 | |
| SCHEMBL6712183 | 0.87 | ALDH1A1 (0.47) | LMNAHIF1ANPSR1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | NPC1 3891/4885LMNA 4062/4885RAB9A 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.